Literature DB >> 23638236

Primary hepatosplenic CD5-positive diffuse large B-cell lymphoma: a case report with literature review.

Xiaohui Zhang1, Manhua Sun, Ling Zhang, Haipeng Shao.   

Abstract

De novo CD5-positive diffuse large B-cell lymphoma (CD5(+) DLBCL) accounts for approximately 10% of DLBCL, and is usually associated with aggressive clinical course. We report a case of CD5(+) DLBCL with primary involvement of the spleen and liver, and no distinct mass lesions or lymphadenopathy. The patient had stage IV disease with bone marrow involvement by lymphoma. The lymphoma cells showed characteristic portal and intrasinusoidal pattern of infiltrate in the liver. The literature was reviewed and the clinicopathologic features of 7 similar reported cases were summarized. All cases share the common features of hepatosplenomegaly without mass lesions, exclusive red pulp infiltrate with a diffuse and cordal pattern in the spleen, portal and intrasinusoidal pattern of infiltrate in the liver, and stage IV disease with poor response to conventional chemotherapy. This may represent a distinct subgroup of CD5(+) DLBCL and the diagnosis is important for prompt clinical treatment.

Entities:  

Keywords:  CD5; diffuse large B-cell lymphoma; hepatosplenomegaly

Mesh:

Substances:

Year:  2013        PMID: 23638236      PMCID: PMC3638115     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  15 in total

1.  De novo CD5+ diffuse large B-cell lymphomas. A heterogeneous group containing an unusual form of splenic lymphoma.

Authors:  S H Kroft; M S Howard; L J Picker; M Q Ansari; D B Aquino; R W McKenna
Journal:  Am J Clin Pathol       Date:  2000-10       Impact factor: 2.493

2.  De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome.

Authors:  M Yamaguchi; T Ohno; K Oka; M Taniguchi; M Ito; K Kita; H Shiku
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

3.  De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients.

Authors:  Motoko Yamaguchi; Masao Seto; Masataka Okamoto; Ryo Ichinohasama; Naoya Nakamura; Tadashi Yoshino; Junji Suzumiya; Takuhei Murase; Ikuo Miura; Takashi Akasaka; Jun-ichi Tamaru; Ritsuro Suzuki; Yoshitoyo Kagami; Masami Hirano; Yasuo Morishima; Ryuzo Ueda; Hiroshi Shiku; Shigeo Nakamura
Journal:  Blood       Date:  2002-02-01       Impact factor: 22.113

4.  De novo CD5+ diffuse large B-cell lymphoma: a distinct subset with adverse features, poor failure-free survival and outcome with conventional therapy.

Authors:  Jason Westin; Peter McLaughlin
Journal:  Leuk Lymphoma       Date:  2010-01

5.  Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Gilles Salles; Daphne de Jong; Wanling Xie; Andreas Rosenwald; Mukesh Chhanabhai; Philippe Gaulard; Wolfram Klapper; Maria Calaminici; Birgitta Sander; Christoph Thorns; Elias Campo; Thierry Molina; Abigail Lee; Michael Pfreundschuh; Sandra Horning; Andrew Lister; Laurie H Sehn; John Raemaekers; Anton Hagenbeek; Randy D Gascoyne; Edie Weller
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

6.  Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.

Authors:  N Niitsu; M Okamoto; J-i Tamaru; T Yoshino; N Nakamura; S Nakamura; K Ohshima; H Nakamine; M Hirano
Journal:  Ann Oncol       Date:  2010-03-15       Impact factor: 32.976

7.  De novo CD5-positive and Richter's syndrome-associated diffuse large B cell lymphomas are genotypically distinct.

Authors:  A Matolcsy; A Chadburn; D M Knowles
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

8.  B-type large-cell primary splenic lymphoma with massive involvement of the red pulp.

Authors:  C Salgado; E Feliu; E Montserrat; N Villamor; J Ordi; J L Aguilar; J L Vives-Corrons; C Rozman
Journal:  Acta Haematol       Date:  1993       Impact factor: 2.195

9.  CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.

Authors:  D Ennishi; K Takeuchi; M Yokoyama; H Asai; Y Mishima; Y Terui; S Takahashi; H Komatsu; K Ikeda; M Yamaguchi; R Suzuki; M Tanimoto; K Hatake
Journal:  Ann Oncol       Date:  2008-06-23       Impact factor: 32.976

10.  B lymphocytic lymphoma (large cell) of possible splenic marginal zone origin presenting with prominent splenomegaly and unusual cordal red pulp distribution.

Authors:  M Palutke; L Eisenberg; S Narang; L L Han; T C Peeples; D L Kukuruga; P M Tabaczka
Journal:  Cancer       Date:  1988-08-01       Impact factor: 6.860

View more
  2 in total

1.  Fever and arthralgia as the initial symptoms of primary bone marrow diffuse large B-cell lymphoma: A case report.

Authors:  Saisai Ren; Yanling Tao; L U Jia; Panpan Cheng; Jilei Zhang; Hao Zhang
Journal:  Oncol Lett       Date:  2016-04-04       Impact factor: 2.967

Review 2.  Jaundice may be the only clinical manifestation of primary hepatosplenic diffuse large B-cell lymphoma: a case report and literature review.

Authors:  Xue Shi; Tingting Zhang; Hong Xu; Xiaoying Zhang; Hongguo Zhao; Xiaodan Liu; Fang Hou; Guangjie Yang; Zhihe Liu
Journal:  J Int Med Res       Date:  2020-08       Impact factor: 1.671

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.